Ex-Bristol-Myers Squibb Exec Admits To Insider Trading

Law360, Washington (June 10, 2013, 7:06 PM EDT) -- A former Bristol-Myers Squibb Co. executive pled guilty Monday to securities fraud charges in New Jersey federal court, admitting he committed insider trading by purchasing stock options in a biotechnology company after learning BMS planned to acquire it.

Robert Ramnarine faces up to 20 years in prison and a $5 million fine after admitting to one count of securities fraud for buying Amylin Pharmaceuticals Inc. stock options in May and June 2012, according to the U.S. attorney's office in New Jersey. BMS announced it had purchased...
To view the full article, register now.